Cagrilintide
Browse our Cagrilintide articles and comparisons. Start with the drug explainer for the mechanism and trial evidence, or choose a comparison below.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Novo Nordisk |
| Mechanism | Long-acting amylin receptor agonist |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~11.5% at 68 weeks (REDEFINE 1 monotherapy) |
| Status | Phase 3 — commercialized as half of CagriSema |
Drug explainer
What Is Cagrilintide? The Amylin Analog Behind CagriSema →An investigational amylin analog studied alone and with semaglutide in CagriSema; trial results and current development explained.
Cagrilintide compared
Comparisons involving Cagrilintide, with the limits of comparing separate trials.
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Compare retatrutide with the cagrilintide–semaglutide combination, including REDEFINE 4 and why separate trial results do not establish superiority.
Updated September 8, 2026
Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist
Evidence for this specific combination is preclinical. CagriSema and eloralintide trials cannot establish a cagrilintide–tirzepatide dosing plan.
Updated September 8, 2026
Related articles
Safety, mechanism, and context pieces that reference Cagrilintide.
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.